2017 - PRESS RELEASES

Written on . Posted in GFB'S Press Releases .

Myonexus Therapeutics Secures $ 2,5 Million Seed Financing to Clinically Advance Limb-Girdle Muscular Dystrophy (LGMD) Gene Theraphies -  December 13th 2017

Clinical Trials Bring Hope to Kids with Spinal Muscular Atrophy  - November 21th  2017

FDA Clears IND Application for Micro-dystrophin Gene Therapy Program to Treat Duchenne  - November 8th 2017

Sarepta & Nationwide Announce FDA Clearance of IND for Micro-Dystrophin Gene Therapy Program for the Treatment of Duchenne – November 6th 2017

Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy – November 2nd 2017

Gene Therapy Continues to Show Promise for Limb-Girdle Muscular Dystrophy – June 13th  2017 

Myonexus Therapeutics, Inc. Launches to Develop Pioneering, Clinical-Stage Gene Therapies Targeting Limb-Girdle Muscular Dystrophies  - June 7th 2017

Myonexus Launches Development of Gene Therapies Targeting Limb-Girdle MD - June 8th 2017

Promising Preclinical results for LGMD gene therapy – Muscular Dystrophy UK - February 8th 2017